JAK1 and acute graft versus host disease: We used ruxolitinib, a JAK1-JAK2 inhibitor that has been approved for the treatment of multiple diseases, such as myelofibrosis, osteofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease.